News from Mt. Sinai on their Panobinostat trial for MF

Drs. Ron Hoffman and John Mascerenhas of Mt. Sinai School of Medicine in New York have reported positive outcomes from their Phase I trial of panobinostat in myelofibrosis patients. Their article published in the British Journal of Haematology states that significant improvement occurred for patients on low dosages of Panobinostat.

Click here for the full article from Mt. Sinai's Medicine Matters blog.

Click here for the study abstract.